A PHASE 2, RANDOMIZED, OPEN-LABEL THREE-ARM CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LENVATINIB (E7080/MK-7902) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) VERSUS STANDARD OF CARE CHEMOTHERAPY AND LENVATINIB MONOTHERAPY IN PARTICIPANTS WITHRECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) THAT HAVE PROGRESSED AFTER PLATINUM THERAPY AND IMMUNOTHERAPY (PD-1/PD-L1 INHIBITORS) (LEAP-009)

Registry ID

MK-7902-009-00 ** SEE NOTES

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

MERCK CANADA INC

Start date

2021-07-28

Last update

2020-06-25

Conditions

• HEAD AND NECK CANCER

Related clinical trials

• A PHASE I/IB STUDY EVALUATING SINGLE-AGENT INAVOLISIB AND INAVOLISIB PLUS ATEZOLIZUMAB IN PIK3CA-MUTATED CANCERS
• PHASE 1/1B STUDY OF AKT INHIBITOR IPATASERTIB WITH CHEMORADIATION FOR LOCALLY ADVANCED HEAD AND NECK CANCER
• NOVEL MRI-GUIDED ULTRASOUND STIMULATED MICROBUBBLE RADIATION TREATMENT FOR PATIENTS WITH HEAD AND NECK CANCER
• "PET/MR OF THE CAROTID ARTERIES WITH 68GA-DOTA-TATE IN PATIENTS FOLLOWING HEAD AND NECK RADIATION THERAPY AND AT RISK OF CEREBROVASCULAR EVENTS."
• RANDOMIZED PHASE II/III TRIAL OF RADIOTHERAPY WITH CONCURRENT MEDI4736 (DURVALUMAB) VS RADIOTHERAPY WITH CONCURRENT CETUXIMAB IN PATIENTS WITH STAGE III-IVB HEAD AND NECK CANCER WITH A CONTRAINDICATION TO CISPLATIN
• KEYSTROKE: A RANDOMIZED PHASE II STUDY OF PEMBROLIZUMAB (KEYTRUDA®) PLUS STEREOTACTIC RE-IRRADIATION VERSUS SBRT ALONE FOR LOCOREGIONALLY RECURRENT OR SECOND PRIMARY HEAD AND NECK CARCINOMA

View on source registry